Anthem Biosciences Limited ANTHEM
NSE · India · Health Technology
INR 855.75-2.85 (-0.33%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Anthem Biosciences Ltd (NSE:ANTHEM) reports robust operational efficiency with a 39.6% EBITDA margin, despite facing revenue timing shifts and regulatory hurdles.
In this week’s edition of InnovationRx, we look at biotech M&A, the rise of India’s Anthem Biosciences, and more.
Anthem Biosciences Ltd (NSE:ANTHEM) reports robust financial performance with significant revenue growth and strategic investments for future capacity expansion.
Anthem Biosciences Ltd (NSE:ANTHEM) reports robust EBITDA margins and strategic growth plans despite facing market challenges and exceptional costs.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.